REG - Haleon PLC - Total Voting Rights and Capital

HALEONAnnouncement

Yesterday 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA0317Za&default-theme=true

RNS Number : 0317Z  Haleon PLC  01 April 2026

 

Haleon plc: Total Voting Rights and Capital

 

01 April 2026: As at 31 March 2026 the total number of shares issued by Haleon
plc ("Haleon" or the "Company") is 8,931,093,261 ordinary shares of £0.01
each, of which 12,548,735 are held as treasury shares.

 

Therefore, the number of ordinary shares with voting rights is 8,918,544,526
and this figure should be used by shareholders (and others with notification
obligations) as the denominator for the calculation by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
(mailto:company.secretary@haleon.com)

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUASBRNWUSRRR



            Copyright 2019 Regulatory News Service, all rights reserved